MiNK Therapeutics announces complete remission in testicular cancer and Phase 2 gastric cancer survival data

MiNK Therapeutics, Inc.

Complete and durable remission in metastatic testicular cancer patient after single infusion of agenT-797 plus nivolumab, per Nature's Oncogene publication.
Phase 2 gastric cancer trial data showed immune activation, tumor infiltration, and survival beyond 12 months in checkpoint-refractory patients.
Separate case report: 42% tumor reduction and >9 months progression-free survival in gastric cancer patient with single agenT-797 infusion plus nivolumab.
Phase 2 trial (NCT06251973) actively enrolling with additional readouts expected.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.